List view / Grid view
7 May 2014 | By kdm communications
Quotient Clinical has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development...
7 May 2014 | By Johnson & Johnson
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning...
7 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S announced that clinical and pre-clinical data highlighting the company’s ongoing commitment to advancing the science and treatment of depression will be presented at the American Psychiatric Association 167th Annual Meeting...
6 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved SYNRIBO® (omacetaxine mepesuccinate) for injection...
6 May 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc., announced the results of its landmark PRIDE trial...
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
6 May 2014 | By Boehringer Ingelheim
Connexios Life Sciences and Boehringer Ingelheim announced an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes...
6 May 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia...
6 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology...
2 May 2014 | By Merck
Merck and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
2 May 2014 | By The European Medicines Agency
The European Medicines Agency has presented the European Commission with its first report on the tasks it undertook during the first year of application of the EU’s new pharmacovigilance legislation...
1 May 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
